SANES

10.196

-0.25%↓

BBVA

18.925

+1.83%↑

BNP

92.01

+1.08%↑

CABK

10.975

+2.52%↑

INGA

25.96

+2.16%↑

SANES

10.196

-0.25%↓

BBVA

18.925

+1.83%↑

BNP

92.01

+1.08%↑

CABK

10.975

+2.52%↑

INGA

25.96

+2.16%↑

SANES

10.196

-0.25%↓

BBVA

18.925

+1.83%↑

BNP

92.01

+1.08%↑

CABK

10.975

+2.52%↑

INGA

25.96

+2.16%↑

SANES

10.196

-0.25%↓

BBVA

18.925

+1.83%↑

BNP

92.01

+1.08%↑

CABK

10.975

+2.52%↑

INGA

25.96

+2.16%↑

SANES

10.196

-0.25%↓

BBVA

18.925

+1.83%↑

BNP

92.01

+1.08%↑

CABK

10.975

+2.52%↑

INGA

25.96

+2.16%↑

Home・Lista de Ações・Ipsen SA.

Ipsen SA.

Fechado

SetorFinanças

165.6 0.67

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

164.5

Máximo

166.2

Indicadores-chave
By Trading Economics
Rendimento	-225M 110M
Vendas	36M 1.9B
P/E Médio do Setor	30.921 57.736
Rendimento de Dividendos	0.84
Margem de lucro	5.899
Funcionários	5,535
EBITDA	-171M 466M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	-12.83% downside

Dividendos
By Dow Jones
Rendimento de Dividendos Médio do Setor	0.84% 4.52%
Próximos Ganhos	30 de jul. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	2.2B 14B
Abertura anterior	164.93
Fecho anterior	165.6

Sentimento de Notícias

By Acuity

45%

55%

160 / 439 Ranking em Finance

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

99.85 / 104 Suporte e Resistência

Ipsen SA. Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

14 de mai. de 2026, 22:44 UTC

Aquisições, Fusões, Aquisições de Empresas

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14 de mai. de 2026, 22:27 UTC

Aquisições, Fusões, Aquisições de Empresas

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14 de mai. de 2026, 22:12 UTC

Ganhos

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14 de mai. de 2026, 21:52 UTC

Aquisições, Fusões, Aquisições de Empresas

LVMH to Sell Marc Jacobs

15 de mai. de 2026, 00:00 UTC

Ganhos

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14 de mai. de 2026, 23:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14 de mai. de 2026, 23:56 UTC

Aquisições, Fusões, Aquisições de Empresas

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14 de mai. de 2026, 23:56 UTC

Aquisições, Fusões, Aquisições de Empresas

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14 de mai. de 2026, 23:56 UTC

Conversa de Mercado

Gold Prices Rise on Strong Demand -- Market Talk

14 de mai. de 2026, 23:56 UTC

Aquisições, Fusões, Aquisições de Empresas

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14 de mai. de 2026, 23:50 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

14 de mai. de 2026, 23:50 UTC

Conversa de Mercado

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14 de mai. de 2026, 23:47 UTC

Ganhos

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14 de mai. de 2026, 23:47 UTC

Ganhos

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14 de mai. de 2026, 23:46 UTC

Ganhos

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14 de mai. de 2026, 23:46 UTC

Ganhos

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14 de mai. de 2026, 23:28 UTC

Conversa de Mercado

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14 de mai. de 2026, 23:00 UTC

Conversa de Mercado

Australia's One Nation Party Leads In The Polls -- Market Talk

14 de mai. de 2026, 22:46 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

14 de mai. de 2026, 22:46 UTC

Conversa de Mercado

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14 de mai. de 2026, 22:46 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

14 de mai. de 2026, 22:35 UTC

Conversa de Mercado

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14 de mai. de 2026, 22:11 UTC

Aquisições, Fusões, Aquisições de Empresas

LVMH Agrees to Sell Marc Jacobs -- WSJ

14 de mai. de 2026, 22:06 UTC

Conversa de Mercado

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14 de mai. de 2026, 22:04 UTC

Ganhos

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14 de mai. de 2026, 22:04 UTC

Ganhos

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14 de mai. de 2026, 22:04 UTC

Ganhos

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14 de mai. de 2026, 22:00 UTC

Ganhos

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14 de mai. de 2026, 21:55 UTC

Ganhos

Nu Holdings 1Q EPS 18c >NU

14 de mai. de 2026, 21:55 UTC

Ganhos

Nu Holdings 1Q Rev $4.97B >NU

Comparação entre Pares

Variação de preço

Ipsen SA. Previsão

Preço-alvo

By TipRanks

-12.83% parte inferior

Previsão para 12 meses

Média 144 EUR -12.83%

Máximo 170 EUR

Mínimo 130 EUR

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Ipsen SA. - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

4 ratings

Comprar

Manter

Vender

Com base em 4 analistas que deram avaliações de ações para Ipsen SA. - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

99.85 / 104Suporte e Resistência

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Sentimento

By Acuity

160 / 439 Ranking em Finanças

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.